Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

58
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
58
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

3.3K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.3K
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

1.0K
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
1.0K
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

62
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
62
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

124
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
124
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

69
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative analysis of LDR and HDR intracavitary brachytherapy in cervical cancer: the critical role of overall treatment time - a decade of experience.

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology·2026
Same author

Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

Clinical pharmacology and therapeutics·2026
Same author

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal for immunotherapy of cancer·2026
Same author

Editorial: Mechanisms and innovations in combating intracellular infections.

Frontiers in microbiology·2026
Same author

Disparities in oral cancer screening among Indian women aged 30-49: insights from a national survey.

Ecancermedicalscience·2026
Same author

Multitask learning of longitudinal circulating biomarkers and clinical outcomes: identification of optimal machine-learning and deep-learning models.

BMC medical informatics and decision making·2026

Related Experiment Video

Updated: Mar 4, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.3K

QT Prolongation Risk of Antibody-Drug Conjugates.

Xu Steven Xu1, Kinjal Sanghavi2, Summer Feng2

  • 1Clinical Pharmacology and Quantitative Science, Genmab Inc., Princeton, NJ, USA. sxu@genmab.com.

Drug Safety
|March 2, 2026
PubMed
Summary

Antibody-drug conjugates (ADCs) show low cardiac risk, but some require monitoring for QT prolongation. Regulatory approaches vary based on drug payload novelty to ensure patient safety.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.1K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K

Related Experiment Videos

Last Updated: Mar 4, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.3K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.1K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Antibody-drug conjugates (ADCs) offer targeted cancer therapy but carry risks of cardiac toxicity, specifically QT interval prolongation.
  • Understanding the mechanisms of ADC-induced QT prolongation is crucial for safe drug development.

Purpose of the Study:

  • To review mechanisms of ADC-induced QT prolongation.
  • To evaluate the cardiac safety of FDA-approved ADCs.
  • To outline a framework for assessing QT prolongation risk in ADC development.

Main Methods:

  • Systematic review of clinical and preclinical data for 14 FDA-approved ADCs.
  • Analysis of ADC classes including auristatins, maytansinoids, and topoisomerase inhibitors.
  • Examination of regulatory review outcomes and labeling recommendations.

Main Results:

  • Most approved ADCs exhibit low corrected QT prolongation risk at therapeutic doses.
  • Inotuzumab and gemtuzumab ozogamicin show clear QT prolongation signals.
  • Auristatin-, maytansinoid-, and topoisomerase-1-based ADCs demonstrate minimal QT changes.

Conclusions:

  • ADC cardiac safety evaluation is guided by payload novelty, influencing regulatory testing requirements.
  • A framework integrating translational and regulatory aspects can enhance cardiac safety assessment for ADCs.
  • Proactive risk evaluation is essential for improving ADC development and patient outcomes.